News Sun sets out $11.75bn takeover play for Organon After downplaying persistent rumours for months, Sun Pharma has broken cover with an $11.75 billion takeover agreement for Organon.
News Data backs GSK's ovarian cancer blockbuster hopes GSK's B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme.
News US judge blocks bid to curb abortion pill access A bid to limit access to the abortion pill mifepristone in the US, while the FDA carries out a review of the drug, has been blocked in the courts.
News NHS cleared to use Astellas' non-hormonal menopause drug Around half a million women will soon be able to access Astellas' Veoza treatment for symptoms like hot flushes associated with menopause.
News Sun Pharma says talk of $10bn Organon bid is 'speculative' India's Sun Pharma has downplayed a rumour that it is in talks to acquire women's health specialist and MSD spinout Organon for $10bn.
R&D A playbook for effective sponsor/CRO partnership Find out more about optimising sponsor/CRO collaboration in an interview on a case study in FI cell therapy.
News GSK gets second cancer drug approval from Nuvalent buy The FDA has cleared GSK's ALK inhibitor Nelkarmi for a form of lung cancer, the second product from its $10.6bn acquisition of Nuvalent.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.